Pipeline

The Science
Recent Publications
N. Bodor, Z. Zubovics, I. Kurucz, S. Sólyom and E. Bodor, “Potent Analogs of Etiprednol Dicloacetate, a Second Generation of Soft Corticosteroids,” J. Pharm. Pharmacol., 69(12), 1745-1753, (2017). [Link]
A. Samir, N. Bodor and T. Imai, “Identification of Esterases Involved in the Metabolism of Two Corticosteroid Soft Drugs,” Biochem. Pharmacol., 127, 82-89 (2017). [Link]
E. T. Bodor, W.-M. Wu, R. Chandran and N. Bodor, “Enhanced Activity of Topical Hydrocortisone by Competitive Binding of Corticosteroid-Binding Globulin,” J. Pharm. Sci., 105, 2873-2878 (2016). [Link]
P. Buchwald and N. Bodor, “Brain-Targeting Chemical Delivery Systems and Their Cyclodextrin-Based Formulations in Light of the Contributions of Marcus E. Brewster,” J. Pharm. Sci., accepted for publication (2016). [Link]
P. Buchwald and N. Bodor, “Recent advances in the design and development of soft drugs,” Proceedings of the 9th Retrometabolism Based Drug Design and Targeting Conference, May 12-15, 2013, Orlando, FL, Pharmazie, 69(6), 403-413 (2014). [Link]
W.-M. Wu, E. T. Bodor, J. Howes and N Bodor, “The effects of ∆1-cortienic acid on skin blanching, pharmacokinetics and stability of loteprednol etabonate,” Proceedings of the 8th Retrometabolism Based Drug Design and Targeting Conference, June 2-4, 2011, Graz, Austria, Pharmazie, 67(5), 406-410 (2012). [Link]
N. Bodor and P. Buchwald, “Retrometabolic Drug Design and Targeting,” book, John Wiley & Sons, ISBN 978-0-470-94945-0, 405 pp. (2012). [Link]
W.-M. Wu, Y. Tang, P. Buchwald and N. Bodor, “Pharmacokinetics and ∆1-cortienic acid excretion after intravenous administration of prednisolone and loteprednol etabonate in rats,” Proceedings of the 7th Retrometabolism Based Drug Design and Targeting Conference, May 10-13, 2009, Orlando FL, Pharmazie, 65(6), 412-416 (2010). [Link]
E. Pinto, B. Zhang, S. Song, N. Bodor, P. Buchwald and G. Hochhaus, “Feasibility of localized immunosuppression: 2. PLA microspheres for the sustained local delivery of a soft immunosuppresent,” Proceedings of the 7th Retrometabolism Based Drug Design and Targeting Conference, May 10-13, 2009, Orlando FL, Pharmazie, 65(6), 429-435 (2010). [Link]
P. Buchwald, N. Bocca, S. Marzorati, G. Hochhaus, N. Bodor, C. Stabler, N. S. Kenyon, L. Inberardi, R. D. Molano, C. Ricordi and A. Pileggi, “Feasibility of localized immunosuppression: 1. Exploratory studies with glucocorticoids in a biohybrid device designed for cell transplantation,” Proceedings of the 7th Retrometabolism Based Drug Design and Targeting Conference, May 10-13, 2009, Orlando FL, Pharmazie, 65(6), 421-428 (2010). [Link]
N. Bodor and P. Buchwald, “Recent advances in retrometabolic drug design (RMDD) and development,” Proceedings of the 7th Retrometabolism Based Drug Design and Targeting Conference, May 10-13, 2009, Orlando FL, Pharmazie, 65(6), 395-403 (2010). [Link]
N. Bodor and P. Buchwald, “Retrometabolism-Based Drug Design and Targeting,” In Burger’s Medicinal Chemistry, Drug Discovery and Development, Vol. 2: Discovering Lead Molecules, 7th ed. (D.J. Abraham, Ed.) Wiley: New York, (2010), chapter 3. [Link]
Selected Patents
N. Bodor, “Enhancement of Activity and/or Duration of Action of Selected Anti-inflammatory Steroids for Topical or Other Local Applications,” U.S. Patent 7,419,971; September 2, 2008. [Link]
N. Bodor, “Enhancement of Activity and/or Duration of Action of Soft Anti-inflammatory Steroids for Topical or Other Local Applications,” U.S. Patent 7,560,448; July 14, 2009. [Link]
N. Bodor, “Transporter Enhanced Corticosteroid Activity,” U.S. Patent 7,687,484;
March 30, 2010. [Link]
N. Bodor, “Transporter-Enhanced Corticosteroid Activity and Methods and Compositions for Treating Dry Eye,” U.S. Patent 7,691,811, April 6, 2010. [Link]
N. Bodor, “Enhancement of Activity and/or Duration of Action of Selected Anti-inflammatory Steroids for Topical or Other Local Applications,” U.S. Patent 7,776,846; August 17, 2010. [Link]
N. Bodor, “Enhancement of Activity and/or Duration of Action of Soft Anti-Inflammatory Steroids for Topical or Other Local Application,” U.S. Patent 7,923,441; April 12, 2011. [Link]
N. Bodor, “Treatment of Eyelid Dermatitis,” U.S. Patent 8,835,410; September 16, 2014. [Link]
N. Bodor, “Soft Anticholinergic Esters,” U.S. Patent 7,399,861; July 15, 2008. [Link]
N. Bodor, “Soft Anticholinergic Zwitterions,” U.S. Patent 7,417,147; August 26, 2008. [Link]
N. Bodor, “Soft Anticholinergic Zwitterions,” U.S. Patent 7,538,219; May 26, 2009. [Link]
N. Bodor, “Soft Anticholinergic Esters,” U.S. Patent 7,576,210; August 18, 2009. [Link]
N. Bodor, “Soft Anticholinergic Zwitterions,” U.S. Patent 8,071,639; December 6, 2011. [Link]
N. Bodor, “Soft Anticholinergic Esters,” U.S. Patent 8,147,809; April 3, 2012. [Link]
N. Bodor, “Soft Anticholinergic Zwitterions,” U.S. Patent 8,568,699; October 29, 2013. [Link]
N. Bodor, “Soft Anticholinergic Esters,” U.S. Patent 8,628,759; January 14, 2014. [Link]
N. Bodor and D. Angulo, “Method of Dosing and Use of Soft Anticholinergic Esters,” U.S. Patent 9,220,707; December 29, 2015. [Link]
N. Bodor and D. Angulo, “Method of Dosing and Use of Soft Anticholinergic Esters,” U.S. Patent 9,492,429; November 15, 2016. [Link]
N. Bodor and D. Angulo, “Method of Dosing and Use of Soft Anticholinergic Esters,” U.S. Patent 9,895,350; February 20, 2018. [Link]
N. Bodor, “Use of Selected Anticholinergic Zwitterions,” US Patent Appl. No. 14/845,645; Notice of Allowance issued July 24, 2018. [Link]